Theranica Secures $45 Million Series C Funding Round
Proceeds to Fund U.S. Commercial Expansion of Migraine Treatment Device, Nerivio® Financing Led by Philadelphia-Based New Rhein Healthcare,…
Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
TRUDHESA Is the First and Only Therapeutic to Use POD technology to Deliver Dihydroergotamine Mesylate (DHE) to the Vascular-Rich…
Study Compares Nerivio to Standard Care Medications for Acute Treatment of Migraine in Adolescents
Peer-Reviewed Study Compares Treatment Results from Migraine Medications to Using Nerivio’s Remote Electrical Neuromodulation Theranica, a prescribed digital therapeutics…
Nerivio Wins 2021 Medical Design Excellence Award
The First Smartphone-Controlled, Prescription Wearable Device for the Acute Treatment of Migraine, Nerivio, Wins Silver at MDEA Theranica, a…
Nerivio Wearable Migraine Therapeutic Now Eligible for Coverage through UpScript’s Telemedicine Platform
Nerivio Patient Savings Program Allows Eligible Patients to Receive the Prescribed Wearable for Acute Treatment of Migraine for…
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Nerivio Usage Grows Significantly Following Indication Expansion to Adolescents Theranica, a prescribed digital therapeutics company developing advanced electroceuticals…
FDA Approves Theranica’s Nerivio® for Acute Treatment of Migraine in Adolescents
The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above Theranica, a prescribed digital therapeutics (PDT)…
U.S. Military Gains Quicker Access to Migraine Relief through FDA-Cleared CEFALY Technology
A new partnership between CEFALY Technology and QB Medical puts wearable medical devices in the hands of health care…